Several studies have shown that PSMA-targeted PET is superior to conventional imaging (CT, MRI and 18F-FDG) in detecting metastases, and some articles have confirmed that PSMA PET/MRI is superior to multiparametric MRI in diagnosing prostate cancer [14–18]. The gene discussed is FOLH1; the disease is prostate carcinoma.